IGF-I, which is a structurally similar peptide to insulin, is released into the myocardium in a paracrine way, then binds to transmembrane tyrosine receptors in cardiomyocytes, and causes activation of the PI3K-Akt pathway to mediate cardiac hypertrophy. Here, AKT1 is linked to cardiac hypertrophy.